{
"id":"mk19_b_hm_t35",
"number":35,
"bookId":"hm",
"title":{
"__html":"Duration of Anticoagulant Therapy for Venous Thromboembolism<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"79f9fc",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 35. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t35"
}
]
},
"Duration of Anticoagulant Therapy for Venous Thromboembolism",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89e6fe",
"class":"col hd l",
"children":[
"Type of Thrombotic Event"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c10f2d",
"class":"col hd l",
"children":[
"Duration of Anticoagulant Therapy"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b01bf7",
"class":"cell txt l",
"children":[
"Superficial vein thrombophlebitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32f593",
"class":"cell txt l",
"children":[
"No anticoagulation suggested"
]
},
" ",
{
"type":"p",
"hlId":"59d8d8",
"class":"cell txt l",
"children":[
"Treat with supportive care (analgesia, warm compresses, and NSAIDs) and image if symptoms progress"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfedb5",
"class":"cell txt l",
"children":[
"Superficial vein thrombosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"245be0",
"class":"cell txt l",
"children":[
"ASH: Anticoagulation for 6 weeks if â‰¥5 cm in length, close to the deep venous system, or other thrombophilic risk factors exist"
]
},
" ",
{
"type":"p",
"hlId":"7ba3af",
"class":"cell txt l",
"children":[
"CHEST: Fondaparinux for 45 days if increased risk for clot progression (extensive SVT; involvement above the knee; severe symptoms; involvement of the greater saphenous vein; history of DVT, PE, or SVT; active cancer; recent surgery)"
]
},
" ",
{
"type":"p",
"hlId":"f35048",
"class":"cell txt l",
"children":[
"If not anticoagulated, follow up in 1 week and image if symptoms are persistent or worsening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9f993",
"class":"cell txt l",
"children":[
"Distal leg DVT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1e7af",
"class":"cell txt li",
"children":[
"No severe symptoms or risk factors for extension (positive D-dimer, close to proximal veins, multiple veins involved, >5 cm clot, active cancer, previous VTE, hospitalization, COVID-19, unprovoked)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"430f0f",
"class":"cell txt l",
"children":[
"Serial imaging over 2 weeks"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2cc38",
"class":"cell txt li",
"children":[
"Severe symptoms or risk factors for extension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47fde1",
"class":"cell txt l",
"children":[
"3-6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0adf97",
"class":"cell txt l",
"children":[
"Proximal leg DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f3b45",
"class":"cell txt li",
"children":[
"Provoked (by surgery, trauma, immobility)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"156c07",
"class":"cell txt l",
"children":[
"ASH: 3-6 months"
]
},
" ",
{
"type":"p",
"hlId":"d67395",
"class":"cell txt l",
"children":[
"CHEST: 3 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cefc09",
"class":"cell txt li",
"children":[
"Unprovoked"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbede",
"class":"cell txt l",
"children":[
"Extended",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e58fa",
"class":"cell txt li",
"children":[
"Recurrent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51eaca",
"class":"cell txt l",
"children":[
"Duration of therapy depends on whether VTE events were provoked or unprovoked"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84086e",
"class":"cell txt l",
"children":[
"Upper extremity DVT, proximal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"320b1d",
"class":"cell txt l",
"children":[
"3 months or as long as a central venous catheter remains in place"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4623c",
"class":"cell txt l",
"children":[
"Cancer-associated DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bba16",
"class":"cell txt l",
"children":[
"As long as the cancer is active or being treated"
]
},
" ",
{
"type":"p",
"hlId":"2c8ea8",
"class":"cell txt l",
"children":[
"ASCO/ASH: LMWH or DOACs are the preferred anticoagulants",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" ",
{
"type":"p",
"hlId":"f6fccc",
"class":"cell txt l",
"children":[
"CHEST: Apixaban, edoxaban, or rivaroxaban"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d20d8c",
"class":"cell txt l",
"children":[
"Chronic thromboembolic pulmonary hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f23578",
"class":"cell txt l",
"children":[
"Extended"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ASCO = American Society of Clinical Oncology; ASH = American Society of Hematology; CHEST = The American College of Chest Physicians; DOAC = direct oral anticoagulant; DVT = deep venous thrombosis; LMWH = low-molecular-weight heparin; PE = pulmonary embolism; SVT = superficial vein thrombosis; VTE = venous thromboembolism."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Decisions regarding duration of anticoagulation must always weigh the risk of VTE recurrence, risk of bleeding, and patient preference."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Indicates long-term anticoagulation therapy with periodic (such as once per year) re-evaluation of the risks, benefits, and burdens of long-term therapy and discussion of new clinical study results and new anticoagulant drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31381464",
"target":"_blank"
},
"children":[
"PMID: 31381464"
]
},
" doi:10.1200/JCO.19.01461"
],
[
"Data from Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693-4738. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33007077",
"target":"_blank"
},
"children":[
"PMID: 33007077"
]
},
" doi:10.1182/bloodadvances.2020001830; and Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:e545-e608. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34352278",
"target":"_blank"
},
"children":[
"PMID: 34352278"
]
},
" doi:10.1016/j.chest.2021.07.055"
]
]
}